Brief: Ultragenyx Announces First Patients Dosed In Phase 3 Program Evaluating Setrusumab (UX143) For The Treatment Of Osteogenesis Imperfecta

Mereo BioPharma

06/07/2023 14:33

July 6 (Reuters) - Mereo Biopharma Group PLC  MAH0y.F :
    * ULTRAGENYX ANNOUNCES FIRST PATIENTS DOSED IN PHASE 3
PROGRAM
EVALUATING SETRUSUMAB (UX143) FOR THE TREATMENT OF OSTEOGENESIS
IMPERFECTA (OI)
    * ULTRAGENYX PHARMACEUTICAL INC - PIVOTAL PHASE 3 PORTION OF
ORBIT
STUDY NOW ENROLLING APPROXIMATELY 195 PEDIATRIC AND YOUNG ADULT
PATIENTS
    * ULTRAGENYX PHARMACEUTICAL INC - NEWLY INITIATED PHASE 3
COSMIC
STUDY NOW ENROLLING APPROXIMATELY 65 YOUNGER PEDIATRIC PATIENTS

Source text for Eikon:  ID:nGNX7c8lgP 
Further company coverage:  MAH0y.F 

 ((reuters.briefs@thomsonreuters.com;))